Product Images Gabapentin
View Photos of Packaging, Labels & Appearance
- Creatinine clearance - gabapentin fig1
- Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
- Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig3
- Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
- Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
- Chemical Structure - gabapentin str
- Label - lbl713352765
Product Label Images
The following 7 images provide visual information about the product associated with Gabapentin NDC 71335-2765 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Creatinine clearance - gabapentin fig1
This text provides a formula for calculating creatinine clearance (Lt) based on age, weight, and gender-specific adjustment for females. The formula involves multiplying age in years by weight in kilograms and then a gender-specific coefficient. It also mentions the coefficient value (0.85) for female patients. This formula can be used in clinical settings to estimate renal function.*
Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
The text provides a graph showing the weekly mean pain scores observed for different treatments in the ITT population in Study 1. The treatments compared are placebo and Gabapentin at a dose of 300 mg/day. The graph shows the changes in pain scores over time for each treatment group.*
Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig3
Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
Not available.*
Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
Chemical Structure - gabapentin str
Label - lbl713352765
This is a description of Gabapentin tablets, USP, containing 800 mg of Gabapentin per film-coated tablet. The tablets are to be stored at a temperature range of 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The tablets should be kept out of reach of children and dispensed in tight, child-resistant containers. The NDC number for these tablets is 71335-2765-1. It is recommended to scan the package insert QR code for complete prescribing information. The tablets are to be repackaged by Bryant Ranch Prepack, Inc. and manufactured by Aurobindo Pharma Limited.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
